X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES SANOFI INDIA VENUS REMEDIES/
SANOFI INDIA
 
P/E (TTM) x -534.0 32.4 - View Chart
P/BV x 0.2 6.5 2.3% View Chart
Dividend Yield % 0.0 1.4 -  

Financials

 VENUS REMEDIES   SANOFI INDIA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
SANOFI INDIA
Dec-16
VENUS REMEDIES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1434,560 3.1%   
Low Rs654,400 1.5%   
Sales per share (Unadj.) Rs324.21,028.5 31.5%  
Earnings per share (Unadj.) Rs6.4129.0 5.0%  
Cash flow per share (Unadj.) Rs40.6186.0 21.8%  
Dividends per share (Unadj.) Rs068.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs366.0753.6 48.6%  
Shares outstanding (eoy) m12.3423.03 53.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.4 7.4%   
Avg P/E ratio x16.234.7 46.7%  
P/CF ratio (eoy) x2.624.1 10.6%  
Price / Book Value ratio x0.35.9 4.8%  
Dividend payout %052.7 0.0%   
Avg Mkt Cap Rs m1,282103,174 1.2%   
No. of employees `0000.93.6 24.9%   
Total wages/salary Rs m2513,592 7.0%   
Avg. sales/employee Rs Th4,430.16,537.7 67.8%   
Avg. wages/employee Rs Th278.0991.4 28.0%   
Avg. net profit/employee Rs Th87.6819.8 10.7%   
INCOME DATA
Net Sales Rs m4,00023,686 16.9%  
Other income Rs m23708 3.2%   
Total revenues Rs m4,02324,394 16.5%   
Gross profit Rs m7855,281 14.9%  
Depreciation Rs m4221,313 32.1%   
Interest Rs m34415 2,291.3%   
Profit before tax Rs m424,661 0.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-371,691 -2.2%   
Profit after tax Rs m792,970 2.7%  
Gross profit margin %19.622.3 88.0%  
Effective tax rate %-87.936.3 -242.2%   
Net profit margin %2.012.5 15.8%  
BALANCE SHEET DATA
Current assets Rs m2,60615,673 16.6%   
Current liabilities Rs m1,9806,678 29.7%   
Net working cap to sales %15.638.0 41.2%  
Current ratio x1.32.3 56.1%  
Inventory Days Days12876 168.8%  
Debtors Days Days4322 193.4%  
Net fixed assets Rs m5,3538,098 66.1%   
Share capital Rs m123230 53.6%   
"Free" reserves Rs m4,39317,088 25.7%   
Net worth Rs m4,51617,356 26.0%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29125,400 32.6%  
Interest coverage x1.1311.7 0.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.9 51.7%   
Return on assets %5.111.8 43.4%  
Return on equity %1.817.1 10.2%  
Return on capital %6.326.9 23.3%  
Exports to sales %024.5 0.0%   
Imports to sales %18.428.0 65.8%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs m7366,627 11.1%   
Fx inflow Rs m07,145 0.0%   
Fx outflow Rs m7366,846 10.8%   
Net fx Rs m-736299 -246.3%   
CASH FLOW
From Operations Rs m9973,226 30.9%  
From Investments Rs m-461-1,555 29.7%  
From Financial Activity Rs m-571-1,818 31.4%  
Net Cashflow Rs m-35-147 23.9%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.2 14.4 1.3%  
FIIs % 0.6 14.6 4.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.5 632.4%  
Shareholders   20,121 15,184 132.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Surges 320 Points; ONGC Tanks 4.5%(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


May 24, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - GLENMARK PHARMA COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS